NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-GM-19-036 from the NIH Guide for Grants and Contracts
Notice NOT-GM-19-037 from the NIH Guide for Grants and Contracts
Notice NOT-DA-19-031 from the NIH Guide for Grants and Contracts
Notice NOT-CA-19-041 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-251 from the NIH Guide for Grants and Contracts. The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks. In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. For projects intended for NIEHS support, the focus may be on innovative technology and method development.
Funding Opportunity PAR-19-252 from the NIH Guide for Grants and Contracts. The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks. In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. For projects intended for NIEHS support, the focus may be on innovative technology and method development.
Funding Opportunity PAR-19-249 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support research to explore the impacts of extreme weather and disaster events on the basic biology of aging. The goal is to fund studies in laboratory animals that will complement and inform studies in the companion FOA on the adverse effects of extreme weather and related disasters in the elderly and adults over the aging life course.
Funding Opportunity PAR-19-250 from the NIH Guide for Grants and Contracts. Background The purpose of this funding opportunity announcement is to advance our understanding of the impact of extreme weather and disaster events in aging human populations. Together with the companion FOA (PAR-19-XXX) that focuses on basic mechanisms of aging utilizing animal models, these two FOAs will help to explicate the behavioral, biological, epigenetic, genetic, neurological and socioecological processes that occur during extreme weather or disaster events and that affect aging processes. Through the integration of the population studies and the companion mechanistic studies FOA, the ultimate goal is to improve the health and well-being of older adults via increased knowledge about extreme weather and disaster preparedness, response, and recovery.
Funding Opportunity PAR-19-253 from the NIH Guide for Grants and Contracts. This initiative will support projects that focus solely on development of technologies with the potential to enable acquisition of basic biomedical knowledge. Projects should be justified in terms of technical innovation, and utility for future biomedical impact. The products of this research will be functioning prototype instruments, methods, synthetic approaches, biological products, etc., characterized adequately to be ready for first application to the type of biomedical research questions that provide the rationale for their development, but application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and would not be funded. Proof of principle for the technology will have already been shown, but there will still be significant fundamental technical challenges. Applications should include preliminary data. Projects that have significant remaining risk but are supported by early feasibility studies might be appropriate for a three year R01 proposal with reduced budget to better manage risk and investment. Projects that are well supported by feasibility studies and propose to develop fully functional prototypes might require higher budgets and a four year duration (five years for early stage investigators). Projects that primarily focus on optimization, hardening, or obvious extrapolations of established technology might be less competitive.
Funding Opportunity PAR-19-254 from the NIH Guide for Grants and Contracts. This initiative will support exploratory research leading to the development of innovative technologies for biomedical research. The program will recognize and reward high risk approaches with potential for significant impact. Projects should entail a high degree of risk or novelty, which will be offset by a correspondingly high potential impact. However, the possible impact is likely to be far off. Application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and would not be funded. The goal of this FOA is to support proof of concept studies for feasibility and exploratory technology development. Feasibility must not have already been established in the literature or with preliminary data. Published data can be used to establish the current state of the art but cannot forecast or predict project outcomes. Preliminary data for any purpose might appear to forecast the likelihood of success. Therefore, no unpublished data is allowed. While unpublished data are not permitted, references and data from widely available preprints that have a Digital Object Identifier (DOI) are acceptable.
Funding Opportunity PAR-19-247 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research to improve existing animal models or develop novel animal models that more accurately represent influenza immunity in humans, with an emphasis on increasing the predictive value of models for evaluating novel universal influenza vaccines.
Funding Opportunity PAR-19-248 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research to improve existing animal models or develop novel animal models that more accurately represent influenza immunity in humans, with an emphasis on increasing the predictive value of models for evaluating novel universal influenza vaccines.
Notice NOT-CA-19-045 from the NIH Guide for Grants and Contracts
Notice NOT-CA-19-044 from the NIH Guide for Grants and Contracts
Notice NOT-NS-19-051 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-098 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HL-20-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks grant applications to optimally and sustainably address late-stage implementation research questions to address scaling up evidence-based interventions at the population level for prevention and management of hypertension in low- and middle-income countries and small island developing states. For the purposes of this FOA, late-stage implementation research is defined as research to identify strategies to achieve sustainable uptake of proven-effective interventions in routine clinical and public health and community-based settings and maximize the positive impact on population health. Each awarded project is to conduct late-stage implementation research in one of six geographical regions (e.g., East Asia and the Pacific; Europe and Central Asia; Latin America and the Caribbean; Middle East and North Africa; South Asia; Sub-Saharan Africa). As a group, awardees will constitute a research alliance for hypertension implementation science research in low-resource settings with capabilities for addressing scale-up of evidence-based interventions at the population level for the prevention and management of hypertension. This program is not intended to support research that can be conducted primarily in and/or by the United States or other high-income institutions that do not meet eligibility criteria. This FOA uses the bi-phasic, milestone driven UG3/UH3 cooperative agreement mechanism. Awards made under this FOA will initially support a two-year milestone-driven needs assessment and planning, with possible transition to an implementation (UH3) phase of up to 4 additional years. Only UG3 projects that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases and are expected to include plans for project management and performance milestones for each phase.
Funding Opportunity RFA-AI-19-030 from the NIH Guide for Grants and Contracts. The objective of this Funding Opportunity Announcement (FOA) is to support the evaluation of early stage diagnostics and novel diagnostic strategies for Tuberculosis (TB) in the context of existing clinical diagnostic algorithms in TB endemic countries. Evaluation studies should focus on: 1) proof-of principle studies of novel diagnostic tests and strategies and 2) provide feedback to diagnostic developers on the performance of the technology and most effective strategy for use of a diagnostic technology in an endemic setting.
Notice NOT-HL-19-693 from the NIH Guide for Grants and Contracts
Notice NOT-HL-19-692 from the NIH Guide for Grants and Contracts